Despite its potential in cancer treatment, first-generation allosteric mTOR inhibitors (including rapamycin) have shown some success in specific tumor types but have not exhibited broad anticancer activity due to the feedback activation of PI3K–PKB signaling and incomplete dephosphorylation of 4E-BPs [44, 46, 58]. This evidence concerns the gene MTOR and neoplasm.